Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 98937L105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
InnoCare Pharma Inc.
13G/A
Amendment 1
|
10.4% |
9/8/2026
Event 8/26/2026
|
|
| InnoCare Pharma Inc. | 10.4% | ||
| Ocean Prominent Limited | 10.4% | ||
| InnoCare Pharma Limited | 10.4% | ||
|
Wellington Management Group LLP
13G
|
10.1% |
9/8/2026
Event 8/31/2026
|
|
| Wellington Management Group LLP | 10.1% | ||
| Wellington Group Holdings LLP | 10.1% | ||
| Wellington Investment Advisors Holdings LLP | 10.1% | ||
| Wellington Management Company LLP | 9.9% | ||
|
Enavate Sciences GP, LLC
13D/A
Amendment 2
|
4.9% |
8/19/2026
Event 8/19/2026
|
|
| Enavate Sciences GP, LLC | 4.9% | ||
| Zebra Aggregator, LP | 4.9% | ||
|
SR One Capital Management, LLC
13D/A
Amendment 2
|
7.7% |
8/17/2026
Event 8/13/2026
|
|
| SR One Capital Management, LLC | 7.7% | ||
| SR One Capital Fund II Aggregator, LP | 3.0% | ||
| SR One Capital Partners II, LP | 3.0% | ||
| Amzl, LP | 2.9% | ||
| SR One Capital SMA Partners, LP | 2.9% | ||
| SR One Capital Opportunities Fund I, LP | 1.8% | ||
| SR One Capital Opportunities Partners I, LP | 1.8% | ||
| Simeon George | 7.7% | ||
|
Moulder Leon O Jr
13D
|
5.1% |
5/5/2026
Event 4/29/2026
|
|
| Moulder Leon O Jr | 5.1% | ||
| Tellus BioVentures, LLC | 2.9% | ||
| Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 | 0.1% | ||
|
Leon O. Moulder, Jr.
13D/A
Amendment 1
|
4.8% |
4/2/2026
Event 3/31/2026
|
|
| Leon O. Moulder, Jr. | 4.8% | ||
| Tellus BioVentures, LLC | 2.8% | ||
| Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 | 0.1% | ||
|
FMR LLC
13G/A
Amendment 4
|
14.3% |
2/5/2026
Event 12/31/2025
|
|
| FMR LLC | 14.3% | ||
| Abigail P. Johnson | 14.3% | ||
|
Leon O. Moulder, Jr.
13D
|
5.2% |
1/14/2026
Event 1/7/2026
|
|
| Leon O. Moulder, Jr. | 5.2% | ||
| Tellus BioVentures, LLC | 3.1% | ||
| Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 | 0.1% | ||
| Novo Holdings A/S 13G/A Amendment 1 | 4.7% |
11/14/2025
Event 9/30/2025
|
|
|
InnoCare Pharma Inc.
13G
|
9.4% |
10/15/2025
Event 10/7/2025
|
|
| InnoCare Pharma Inc. | 9.4% | ||
| Ocean Prominent Limited | 9.4% | ||
| InnoCare Pharma Limited | 9.4% | ||
|
Enavate Sciences GP, LLC
13D/A
Amendment 1
|
7.3% |
10/14/2025
Event 10/9/2025
|
|
| Enavate Sciences GP, LLC | 7.3% | ||
| Zebra Aggregator, LP | 7.3% | ||
|
SR One Capital Management, LLC
13D/A
Amendment 1
|
9.4% |
10/14/2025
Event 10/9/2025
|
|
| SR One Capital Management, LLC | 9.4% | ||
| SR One Capital Fund II Aggregator, LP | 3.6% | ||
| SR One Capital Partners II, LP | 3.6% | ||
| Amzl, LP | 3.6% | ||
| SR One Capital SMA Partners, LP | 3.6% | ||
| SR One Capital Opportunities Fund I, LP | 2.2% | ||
| SR One Capital Opportunities Partners I, LP | 2.2% | ||
| Simeon George | 9.4% | ||
|
Longitude Capital Partners IV, LLC
13D/A
Amendment 1
|
4.9% |
10/14/2025
Event 10/9/2025
|
|
| Longitude Capital Partners IV, LLC | 3.4% | ||
| Longitude Venture Partners IV, L.P. | 3.4% | ||
| Longitude Prime Partners, LLC | 1.4% | ||
| Longitude Prime Fund, L.P. | 1.4% | ||
| Patrick G. Enright | 4.9% | ||
| Juliet Tammenoms Bakker | 4.9% | ||
|
Leon O. Moulder, Jr.
13D/A
Amendment 1
|
4.8% |
10/9/2025
Event 10/7/2025
|
|
| Leon O. Moulder, Jr. | 4.8% | ||
| Tellus BioVentures, LLC | 3.1% | ||
| Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 | 0.1% | ||
|
FMR LLC
13G/A
Amendment 3
|
11.0% |
9/8/2025
Event 8/29/2025
|
|
| FMR LLC | 11.0% | ||
| Abigail P. Johnson | 11.0% | ||
|
FMR LLC
13G/A
Amendment 2
|
7.9% |
8/6/2025
Event 6/30/2025
|
|
| FMR LLC | 7.9% | ||
| Abigail P. Johnson | 7.9% | ||
|
Leon O. Moulder, Jr.
13D
|
5.0% |
6/6/2025
Event 5/30/2025
|
|
| Leon O. Moulder, Jr. | 5.0% | ||
| Tellus BioVentures, LLC | 4.0% | ||
|
FMR LLC
13G/A
Amendment 1
|
6.8% |
5/12/2025
Event 3/31/2025
|
|
| FMR LLC | 6.8% | ||
| Abigail P. Johnson | 6.8% | ||
| Novo Holdings A/S 13G | 5.3% |
4/1/2025
Event 3/25/2025
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 8 | 1.19 k | $32.2 k |
| 2026 Q2 | 149 | 62.0 M | $1.58 B |
| 2026 Q1 | 146 | 57.8 M | $1.14 B |
| 2025 Q4 | 136 | 42.8 M | $1.55 B |
| 2025 Q3 | 82 | 34.8 M | $775 M |
| 2025 Q2 | 75 | 34.1 M | $330 M |
| 2025 Q1 | 68 | 32.5 M | $257 M |
| 2024 Q4 | 67 | 31.7 M | $260 M |
| 2024 Q3 | 45 | 24.8 M | $419 M |